undamentalytics Newsletter
Sign in

Lexicon Pharmaceuticals, Inc. revenue

Lexicon Pharmaceuticals, Inc.'s revenue was $49.8m in fiscal 2025, up 60.2% on the year before. Since fiscal 2009 ($10.7m) it has grown at a compound 10.1% a year. Over the last twelve months it was $41.5m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1152122313079926332224001315041
Growth on the year before—−54.1%−62.3%−41.1%+104.0%+928.5%+468.9%−39.0%+15.7%−31.1%+409.5%−92.5%−98.8%−53.4%+766.2%+>999%+60.2%—
Gross profit———————79906131922001305041
Gross margin———————100.0%97.9%96.1%99.0%92.0%100.0%100.0%92.9%98.0%99.4%99.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses $45M 90.6% ▲ 80.0%
Products $4.6M 9.4% ▼ 22.6%

From Lexicon Pharmaceuticals, Inc.'s 10-K filed March 5, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Lexicon Pharmaceuticals, Inc. $41.5m -29.0% 366.7%
Cue Biopharma, Inc. $37.7m 354.4% 176.2%
Sutro Biopharma, Inc. $45.7m -56.3% -7.0%
Zymeworks Inc. $37.1m -69.8% -56.4%
Nanobiotix S.a. $36.9m 678.4% —
Foghorn Therapeutics Inc. $36.7m 52.0% 19.1%

Compare with peers

Head to head: CUE vs LXRXLXRX vs STROLXRX vs ZYME

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lexicon Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lexicon Pharmaceuticals, Inc.